Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization

Rhea-AI Summary

SOHM Inc. (OTC:SHMN) has appointed Dr. Leonardo Mirandola as Advisory Board Member to advance its CAR-T cell projects toward clinical trials. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, previously served as CSO and Interim COO at Kiromic Biopharma, where he developed therapies including an FDA Fast-Track-designated allogeneic gamma-delta T-cell therapy for Stage 4 non-small cell lung cancer.

SOHM is leveraging its proprietary gene editing platform, ABBIE, to enhance CAR-T cell therapy commercialization. ABBIE offers advantages over traditional viral-based or CRISPR systems, including cost-efficiency, reduced manufacturing complexity, and fewer regulatory hurdles. The company aims to improve production timelines, genetic payload fidelity, and therapeutic window accessibility.

Positive

• Appointment of highly experienced Dr. Mirandola with proven track record in clinical translation
• Dr. Mirandola's previous success with FDA Fast-Track-designated therapy development
• Proprietary ABBIE platform offers cost-efficient advantages over traditional gene-editing systems
• Potential for streamlined production and broader therapeutic applications

Negative

• CAR-T cell projects still in pre-clinical phase
• No timeline provided for clinical trials initiation
• Uncertain regulatory pathway ahead

CHINO HILLS, CA / ACCESS Newswire / May 2, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces Dr. Leonardo Mirandola joined the Company as Advisory Board Member. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, will spearhead the company's initiatives to advance its CAR-T cell projects toward clinical trials.

Dr. Mirandola brings a wealth of expertise in operational management, R&D, and clinical development, with a proven track record in transforming innovative scientific breakthroughs into viable treatment options. He holds a Ph.D. and a Master's degree from the University of Milano, Italy.

"Dr. Mirandola's extensive background in cell therapy and his remarkable success in clinical translation make him an invaluable addition to our team," said David Aguilar of SOHM Inc. "His leadership will be instrumental as we push the boundaries of CAR-T cell production and therapy and strive to bring new treatment options to those battling cancer."

Before joining SOHM Inc., Dr. Mirandola served as Chief Scientific Officer and Interim Chief Operations Officer at Kiromic Biopharma, where he played a pivotal role in developing and overseeing clinical operations for various groundbreaking therapies. His contributions led to the advancement of an autologous dendritic cell therapeutic vaccine for solid tumors and an allogeneic gamma-delta T-cell therapy, which has received Fast-Track-designation by the FDA and showed positive results in Phase 1 trials for patients with Stage 4 non-small cell lung cancer.

Dr. Mirandola has a remarkable record of securing patents for novel manufacturing techniques and AI-driven target discovery processes, which have significantly advanced the understanding and development of cell therapies. His leadership in establishing cGMP-compliant manufacturing processes will be critical as SOHM Inc. prepares its CAR-T cell projects for rigorous clinical evaluation.

"I am excited to join SOHM Inc. and collaborate with such a talented team dedicated to making a difference in the lives of cancer patients," said Dr. Mirandola.

SOHM, Inc. is harnessing the power of ABBIE, its proprietary gene editing platform, to accelerate and enhance the commercialization of CAR-T cell therapies. Unlike traditional viral-based or CRISPR systems, ABBIE offers a cost-efficient editing approach that significantly reduces manufacturing complexity and regulatory hurdles. By integrating ABBIE into its CAR-T development pipeline, SOHM aims to streamline production timelines, improve genetic payload fidelity, and broaden the therapeutic window - ultimately making advanced cell therapies more accessible and scalable for a wider range of cancer patients.

For further information on SOHM Inc. and its latest advancements in biotechnology, please visit www.sohm.com (http://www.sohm.com).

About SOHM, Inc.:

SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.

For further information regarding this announcement or to explore potential collaborations, please contact:

SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700

Safe Harbor Statement:

This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.

SOURCE: SOHM, Inc

View the original press release on ACCESS Newswire

FAQ

Who is Dr. Leonardo Mirandola and what is his role at SOHM (SHMN)?

Dr. Leonardo Mirandola is a biopharma scientist with over 10 years of experience in oncology and cell therapy who joined SOHM as Advisory Board Member to lead their CAR-T cell projects toward clinical trials. He previously served as CSO and Interim COO at Kiromic Biopharma.

What is SOHM's ABBIE platform and how does it differ from traditional gene-editing systems?

ABBIE is SOHM's proprietary gene editing platform that offers a more cost-efficient approach compared to traditional viral-based or CRISPR systems, with reduced manufacturing complexity and fewer regulatory hurdles.

What are Dr. Mirandola's previous achievements in cell therapy development?

Dr. Mirandola developed an autologous dendritic cell therapeutic vaccine for solid tumors and an FDA Fast-Track-designated allogeneic gamma-delta T-cell therapy that showed positive Phase 1 results for Stage 4 non-small cell lung cancer.

How will SOHM's CAR-T cell therapy development benefit from the ABBIE platform?

ABBIE is expected to streamline production timelines, improve genetic payload fidelity, and broaden the therapeutic window, making advanced cell therapies more accessible and scalable for cancer patients.